Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 15, 2025
Reporting period
Not applicable
Filed with the SEC
Nov 18, 2025
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001183553-25-000006
Filed / recorded
Nov 18, 2025, 10:53 PM UTC
Added to OQRO
Oct 8, 2026, 2:37 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Xtant Medical Holdings, Inc.
Issuer CIK
1453593
Ticker
XTNT
Reporting person
John K Bakewell
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Nov 15, 2025
Transaction code
A
Shares / units
158,228
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
914,116
Ownership form
Direct
Amendment
Yes (Form 4/A)
Footnotes from the filing
These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.
Includes 465,570 shares issuable upon settlement of DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.
The purpose of this Form 4 amendment is to correct the number of shares beneficially held in column 5.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.